Results from a recent study showed potential associations between vitamin D levels and the risk of developing atopic dermatitis.

News

News
Thursday, February 18, 2016
Otsuka Pharmaceutical Co., Ltd. and Medimetriks Pharmaceuticals, Inc. entered into a licensing agreement granting Medimetriks exclusive US development and commercialization rights as well as manufacturing rights for OPA-15406, an investigational topical, non-steroidal phosphodiesterase IV (PDE-4) inhibitor, which is a new treatment class for atopic dermatitis.
News
Friday, March 13, 2015
All three products in its newest product line, CeraVe Baby (Valeant Pharmaceuticals North America LLC) have been awarded the National Eczema Association (NEA) Seal of Acceptance, which maintains rigorous standards for approval. Three-step skincare regimen was developed with pediatric dermatologists to help protect and maintain the skin barrier of babies.
News
Thursday, February 26, 2015
Recent study results with dupilumab, a fully-human monoclonal antibody against the interleukin-4 receptor-α, presented in a poster at American Academy of Allergy, Asthma, and Immunology1 annual meeting, demonstrated symptomatic efficacy in atopic dermatitis .

Research in Review

Research in Review
Monday, June 15, 2009
Despite some bumps, The Eczema Center at Rady Children’s Hospital in San Diego is making headway toward showing that dedicated services can improve care.
Research in Review
Thursday, September 4, 2008
As most of you already know, it’s been roughly 40 years since a new class of topical medications for eczema has been introduced.
Research in Review
Thursday, September 4, 2008
In the world of modern dermatology, treating contact dermatitis may not have the cache of phototherapy or the challenge of skin cancer treatment.
Research in Review
Thursday, September 4, 2008
Eczematous dermatitis is associated with impairment of epidermal barrier function, leading to increased transepidermal water loss. Patient education regarding proper general skin care is a vital component of treatment success. This article reports results from a randomized, comparative, 6-week trial evaluating a branded skin cleanser versus a soap-based cleanser in patients undergoing treatment of eczematous dermatitis with clocortolone pivalate 0.1% cream (Cloderm Cream) (n=50). The duration of treatment ranged from 3 weeks to 8 weeks, depending on response to therapy. A